ale-0540 and Inflammation

ale-0540 has been researched along with Inflammation* in 1 studies

Other Studies

1 other study(ies) available for ale-0540 and Inflammation

ArticleYear
Characterization of antiallodynic actions of ALE-0540, a novel nerve growth factor receptor antagonist, in the rat.
    The Journal of pharmacology and experimental therapeutics, 1999, Volume: 289, Issue:3

    There is growing evidence that nerve growth factor (NGF) may function as a mediator of persistent pain states. We have identified a novel nonpeptidic molecule, ALE-0540, that inhibits the binding of NGF to tyrosine kinase (Trk) A or both p75 and TrkA (IC50 5.88 +/- 1. 87 microM, 3.72 +/- 1.3 microM, respectively), as well as signal transduction and biological responses mediated by TrkA receptors. ALE-0540 was tested in models of neuropathic pain and thermally-induced inflammatory pain, using two routes of administration, a systemic i.p. and a spinal intrathecal (i.th.) route. Morphine was also tested for comparison in the antiallodynia model using mechanical stimuli. We show that either i.p. or i.th. administration of ALE-0540 in rats produced antiallodynia in the L5/L6 ligation model of neuropathic pain. The calculated A50 values (and 95% confidence intervals) for ALE-0540 administered i.p. and i. th. were 38 (17.5-83) mg/kg and 34.6 (17.3-69.4) microgram, respectively. ALE-0540 given i.th., at doses of 30 and 60 microgram, also blocked tactile allodynia in the thermal sensitization model. Although morphine displayed greater potency [A50 value of 7.1 (5.6-8. 8) mg/kg] than ALE-0540 in anti-allodynic effect when given i.p. to L5/L6-ligated rats, it was not active when administered i.th. These data suggest that a blockade of NGF bioactivity using a NGF receptor antagonist is capable of blocking neuropathic and inflammatory pain and further support the hypothesis that NGF is involved in signaling pathways associated with these pain states. ALE-0540 represents a nonpeptidic small molecule which can be used to examine mechanisms leading to the development of agents for the treatment of pain.

    Topics: Analgesics; Animals; Cells, Cultured; Chick Embryo; Dose-Response Relationship, Drug; Ganglia, Spinal; Heterocyclic Compounds, 3-Ring; Hot Temperature; Inflammation; Injections, Intraperitoneal; Injections, Spinal; Mice; Morphine; Nerve Growth Factors; Neuralgia; Neurites; Neurons, Afferent; Pain; Phosphorylation; Proto-Oncogene Proteins; Radioligand Assay; Rats; Receptor Protein-Tyrosine Kinases; Receptor, trkA; Receptors, Nerve Growth Factor; Spinal Cord; Spinal Nerves

1999